PharmaCyte Biotech, Inc. (PMCB) Ownership
PMCB ownership summary
as of October 18, 2026- Institutions
- 7.1% of shares outstanding
- Insiders
- 5.74% of shares outstanding
- Shares outstanding
- 10.7M
- Float
- 10.1M shares available to trade
- Short interest
- 1.32% 134K shares short
- Days to cover
- 0.35 short interest up 90.1% vs prior month
- Institutions 7.11%
- Insiders 5.74%
- Other investors 87.15%
PMCB top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Citadel Advisors Llc | 2.64% | 283K | $96,406 | −76,166 (−21.2%) | June 30, 2026 |
| 2 | Geode Capital Management, LLC | 1.16% | 124K | $42,269 | −71,413 (−36.5%) | June 30, 2026 |
| 3 | Vanguard Capital Management, LLC | 0.53% | 57K | $19,316 | +5,311 (+10.3%) | June 30, 2026 |
| 4 | Susquehanna International Group, LLP | 0.42% | 45K | $15,259 | +44,853 (0.0%) | June 30, 2026 |
| 5 | Renaissance Technologies Corp | 0.35% | 38K | $12,923 | −18,513 (−32.8%) | June 30, 2026 |
| 6 | XTX Topco Ltd | 0.32% | 34K | $11,628 | −18,182 (−34.7%) | June 30, 2026 |
| 7 | Northern Trust Corp | 0.30% | 33K | $11,099 | −2,977 (−8.4%) | June 30, 2026 |
| 8 | Jane Street Group LLC | 0.28% | 30K | $10,228 | +18,534 (+160.7%) | June 30, 2026 |
| 9 | Schonfeld Strategic Advisors LLC | 0.25% | 27K | $9,160 | −83 (−0.3%) | June 30, 2026 |
| 10 | Vanguard Fiduciary Trust Co | 0.22% | 23K | $7,978 | — | June 30, 2026 |
| 11 | EQUITEC PROPRIETARY MARKETS, LLC | 0.21% | 22K | $7,562 | — | June 30, 2026 |
| 12 | Commonwealth Equity Services, LLC | 0.19% | 20K | $6,891 | +9,942 (+96.4%) | June 30, 2026 |
| 13 | HRT FINANCIAL LLC | 0.14% | 15K | $5,256 | −9,290 (−37.5%) | June 30, 2026 |
| 14 | Tower Research Capital LLC | 0.05% | 4,888 | $1,663 | −1 (−0.0%) | June 30, 2026 |
| 15 | UBS Group AG | 0.04% | 4,142 | $1,409 | −377 (−8.3%) | June 30, 2026 |
| 16 | Group One Trading, LLC | <0.01% | 500 | $170 | −1,285 (−72.0%) | June 30, 2026 |
| 17 | Advisor Group Holdings, Inc. | <0.01% | 303 | $103 | +1 (+0.3%) | June 30, 2026 |
| 18 | Covestor Ltd | <0.01% | 275 | $94 | — | June 30, 2026 |
| 19 | Barclays PLC | <0.01% | 192 | $65 | +192 (0.0%) | June 30, 2026 |
| 20 | Sachetta LLC | <0.01% | 14 | $5 | — | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 6 holders added 79K shares and 10 cut 198K.
PMCB top mutual fund and ETF holders
4 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Extended Market Index | 0.54% | 58K | $19,812 | −313 (−0.5%) | August 31, 2026 |
| 2 | Fidelity Nasdaq Composite Index | 0.16% | 17K | $5,936 | — | August 31, 2026 |
| 3 | Fidelity Total Market Index | 0.14% | 15K | $5,190 | — | August 31, 2026 |
| 4 | Fidelity Series Total Market Index | 0.12% | 13K | $4,387 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
PMCB insider transactions
latest 4| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-07 | Jonathan Schechter | Buy | $0.84 | 20,000 | $16,800 |
| 2026-01-07 | Joshua Silverman | Buy | $0.83 | 40,000 | $33,200 |
| 2026-01-05 | Jonathan Schechter | Buy | $0.78 | 20,000 | $15,600 |
| 2026-01-05 | Joshua Silverman | Buy | $0.78 | 30,000 | $23,400 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
PMCB shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns PMCB
Institutional investors own 7.1% of PharmaCyte Biotech's shares and insiders 5.74%. The largest holder is Citadel Advisors Llc with 2.64% of the shares (283K), as of June 30, 2026. Among the top 20 institutions, 6 added shares and 10 reduced their stake in the latest filings. Short interest is 1.32% of the float, or 0.35 days of average trading volume. The share count rose 1,349.3% since 2014.
Related: PMCB key metrics. See the PMCB stock overview for the latest quote and news.
PMCB ownership FAQ
Who owns the most PharmaCyte Biotech stock?
The largest shareholders of PharmaCyte Biotech are Citadel Advisors Llc (2.64%), Geode Capital Management, LLC (1.16%), Vanguard Capital Management, LLC (0.53%), Susquehanna International Group, LLP (0.42%), Renaissance Technologies Corp (0.35%).
What percentage of PharmaCyte Biotech is owned by institutions?
Institutions hold 7.1% of PharmaCyte Biotech's shares outstanding; insiders hold 5.74%.
Which funds own PharmaCyte Biotech?
The largest fund holders of PharmaCyte Biotech are Fidelity Extended Market Index (0.54%), Fidelity Nasdaq Composite Index (0.16%), Fidelity Total Market Index (0.14%), Fidelity Series Total Market Index (0.12%).
What is PharmaCyte Biotech's short interest?
134K shares of PharmaCyte Biotech were sold short, 1.32% of the float; at the average daily volume it would take 0.35 days to cover.
Are insiders buying or selling PharmaCyte Biotech?
Of the latest 4 reported insider transactions in PharmaCyte Biotech (since January 5, 2026), 4 were purchases and 0 were sales.
How many shares of PharmaCyte Biotech are outstanding?
PharmaCyte Biotech has 10.7M shares outstanding, of which 10.1M are in the public float.